🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Imbruvica is a cancer treatment that is marketed by AbbVie. It carries a list price of over $220,000 per year. We investigated the patenting strategies around Imbruvica. Here's what we found: 📄195 patent applications have been filed 📄96 patents have been granted These

Btw, Merck is using the PTAB, a mechanism to review wrongly-granted patents, to challenge Halozyme’s patents. Ironically, PhRMA, where Merck is a long-standing member, is lobbying to pass the PREVAIL Act to gut that very mechanism.

Big drugmakers are abusing the drug patent process to generate extra revenue at the cost of patients, according to a new report. levernews.com/drugmakers-sec…

Big Pharma is taking advantage of the patent system to keep the price of essential medications high, filing dozens of patents for slight modifications to the same drug to keep generics off the market. jacobin.com/2025/06/big-ph…

“We want to expose how the patent system has become a tool to drive the business model and financial gain…It’s a corruption of the patent system” Tahir Amin walks through our new Overpatented, Overpriced report with The Lever levernews.com/drugmakers-sec…

Our own Tahir Amin joined The Hill's Niall Stanage to discuss what we uncovered in our latest report.

TAHIR AMIN: Novo Nordisk spends more on buying back shares and paying off its shareholders than it does on R&D…This idea that [pharma companies] need to charge higher prices so that they can do the R&D is actually not entirely true.